Heterogeneity of tumor immune microenvironment and real-world analysis of immunotherapy efficacy in lung adenosquamous carcinoma
暂无分享,去创建一个
X. Yi | Cheng Huang | Zhijie Wang | Jun Zhao | Q. Miao | Chengzhi Zhou | Weifeng Zhu | Wenjie Zhong | Q. Chu | G. Lin | B. Zhu | Xiaobin Zheng | Xinlong Zheng | Jie Hu | Haibo Wang | Longfeng Zhang | Xuefeng Xia | Chao Li | Shan-Jun Yang | Biao Wu | K. Jiang | Pansong Li | Lin Wu | Hui Guo | Yiquan Xu | Yujing Li | Huijuan Wang | F. Wu | Weijin Xiao | Qian Li | Shiwen Wu
[1] L. Bubendorf,et al. Deciphering the clonal relationship between glandular and squamous components in adenosquamous carcinoma of the lung using whole exome sequencing. , 2020, Lung cancer.
[2] A. Santarelli,et al. The immune phenotype of tongue squamous cell carcinoma predicts early relapse and poor prognosis , 2020, Cancer medicine.
[3] W. Liang,et al. Genomic origin and EGFR-TKI treatments of pulmonary adenosquamous carcinoma. , 2020, Annals of oncology : official journal of the European Society for Medical Oncology.
[4] H. Hou,et al. The role of MDM2 amplification and overexpression in therapeutic resistance of malignant tumors , 2019, Cancer Cell International.
[5] E. V. Van Allen,et al. Mechanisms of Resistance to Immune Checkpoint Blockade: Why Does Checkpoint Inhibitor Immunotherapy Not Work for All Patients? , 2019, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.
[6] P. A. Futreal,et al. Local mutational diversity drives intratumoral immune heterogeneity in non-small cell lung cancer , 2018, Nature Communications.
[7] T. Sudo,et al. PD-L1 expression in pancreatic adenosquamous carcinoma: PD-L1 expression is limited to the squamous component. , 2018, Pathology, research and practice.
[8] T A Chan,et al. Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.
[9] S. Gettinger,et al. Nivolumab Plus Erlotinib in Patients With EGFR‐Mutant Advanced NSCLC , 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[10] Hongyang Lu,et al. Adenosquamous carcinoma of the lung , 2018, OncoTargets and therapy.
[11] Tao Jiang,et al. Heterogeneity of PD‐L1 Expression Among the Different Histological Components and Metastatic Lymph Nodes in Patients With Resected Lung Adenosquamous Carcinoma , 2018, Clinical lung cancer.
[12] F. Marincola,et al. International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study , 2018, The Lancet.
[13] R. Weinberg,et al. Understanding the tumor immune microenvironment (TIME) for effective therapy , 2018, Nature Medicine.
[14] Inge M. N. Wortel,et al. Eight-Color Multiplex Immunohistochemistry for Simultaneous Detection of Multiple Immune Checkpoint Molecules within the Tumor Microenvironment , 2018, The Journal of Immunology.
[15] V. Gebski,et al. Clinical and Molecular Characteristics Associated With Survival Among Patients Treated With Checkpoint Inhibitors for Advanced Non–Small Cell Lung Carcinoma: A Systematic Review and Meta-analysis , 2017, JAMA oncology.
[16] M. Delgado-Rodríguez,et al. Systematic review and meta-analysis. , 2017, Medicina intensiva.
[17] Yuanyuan Liu,et al. PD-L1 expression in lung adenosquamous carcinomas compared with the more common variants of non-small cell lung cancer , 2017, Scientific Reports.
[18] B. Knebelmann,et al. Case report and literature review , 2016, Medicine.
[19] S. Digumarthy,et al. EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non–Small Cell Lung Cancer: A Retrospective Analysis , 2016, Clinical Cancer Research.
[20] A. Nicholson,et al. Introduction to The 2015 World Health Organization Classification of Tumors of the Lung, Pleura, Thymus, and Heart. , 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[21] Mikhail Shugay,et al. MiXCR: software for comprehensive adaptive immunity profiling , 2015, Nature Methods.
[22] T. Nielsen,et al. The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.
[23] R. Emerson,et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance , 2014, Nature.
[24] P. Mordant,et al. Adenosquamous carcinoma of the lung: surgical management, pathologic characteristics, and prognostic implications. , 2013, The Annals of thoracic surgery.
[25] A. Borczuk,et al. Thymidylate synthase expression and molecular alterations in adenosquamous carcinoma of the lung , 2013, Modern Pathology.
[26] H. Maeda,et al. Adenosquamous carcinoma of the lung: surgical results as compared with squamous cell and adenocarcinoma cases. , 2012, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.
[27] E. Ruffini,et al. Adenosquamous lung carcinomas: a histologic subtype with poor prognosis. , 2011, Lung cancer.
[28] Naobumi Tochigi,et al. Adenosquamous carcinoma of the lung: a microdissection study of KRAS and EGFR mutational and amplification status in a western patient population. , 2011, American journal of clinical pathology.
[29] Pornpimol Charoentong,et al. Coordination of intratumoral immune reaction and human colorectal cancer recurrence. , 2009, Cancer research.
[30] Hoguen Kim,et al. Identical epidermal growth factor receptor mutations in adenocarcinomatous and squamous cell carcinomatous components of adenosquamous carcinoma of the lung , 2007, Cancer.
[31] E. Shimizu,et al. Squamous Cell Carcinoma Transformation from EGFR‐mutated Lung Adenocarcinoma: A Case Report and Literature Review , 2018, Clinical lung cancer.
[32] Nagarjun Rao. Adenosquamous carcinoma. , 2014, Seminars in diagnostic pathology.
[33] H. Sasaki,et al. Mutation of epidermal growth factor receptor gene in adenosquamous carcinoma of the lung. , 2007, Lung cancer.
[34] M. F. Parry,et al. A Retrospective Analysis , 1990 .